Veracyte

Veracyte FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Veracyte (VCYT) as of Oct 10, 2026 is 190.84 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 264.35 % — a change of -27.81% (lower).

FCF Conversion

190.84 %

YoY

-27.81%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Veracyte is 2025 190.84 % . FCF Conversion Rate (FCF/EBITDA) of Veracyte was 2024 264.35 % . It decreases by -27.81% lower compared to the previous year.

The Veracyte FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
66.94 USD
Jan 1, 2019
47.53 USD
Jan 1, 2020
35.94 USD
Jan 1, 2021
48.96 USD
Jan 1, 2022
2.77 USD
Jan 1, 2023
-46.05 USD
Jan 1, 2024
264.35 USD
Jan 1, 2025
190.84 USD
The Veracyte FCF Conversion history
YEARFCF ConversionYoY
190.84 %-27.81%
264.35 %-674.09%
-46.05 %-1,760.24%
2.77 %-94.34%
48.96 %+36.21%
35.94 %-24.37%
47.53 %-29.00%
66.94 %-19.16%
82.80 %-19.35%
102.66 %+4.44%
98.30 %-2.64%
100.96 %—
Access this data via the Eulerpool API

Veracyte Stock analysis

What does Veracyte do? Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veracyte stock

FCF Conversion Rate (FCF/EBITDA) of Veracyte is 190.84 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Veracyte changed from 264.35 % to 190.84 %, representing a -27.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Veracyte since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Veracyte with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Veracyte

All Key Metrics — Veracyte